Quest Diagnostics Inc. DGX

Quest Diagnostics Incorporated es un proveedor de servicios de información diagnóstica. La Compañía opera a través del segmento DIS, que proporciona servicios de información diagnóstica a una variedad de clientes, incluidos pacientes, médicos, hospitales, redes integradas de prestación de servicios de salud (IDNs), planes de salud, empleadores, organizaciones de atención responsable (ACOs) y entidades de contratos directos (DCEs). También se dedica a dos operaciones comerciales, Servicios de Información Diagnóstica, que desarrolla y ofrece servicios de información diagnóstica que proporciona información a una variedad de clientes, y el grupo de Soluciones Diagnósticas incluye su negocio de servicios de evaluación de riesgos, que ofrece soluciones para aseguradoras y sus negocios de tecnología de información de salud, que ofrece soluciones para proveedores de atención médica. Los servicios de la Compañía se proporcionan principalmente bajo la marca Quest Diagnostics, pero también ofrece servicios bajo otras marcas, incluidas AmeriPath, Dermpath Diagnostics, ExamOne y Quanum.

Con 4 acciones de DGX (USD 928,68) habrías recibido USD 13,52 en dividendos en los últimos 12 meses.

DGX hizo una división de acciones (split) de 2:1 el 21 de junio de 2005: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 5 oct

  Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

  Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

  

• GlobeNewswire Inc. 24 sept

  Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

  The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

  

• Zacks Investment Research 22 sept

  Is This the Right Time to Add DGX Stock to Your Portfolio?

  Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.

  

• Zacks Investment Research 21 sept

  Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus

  Zacks Investment Research showcased strong performance across its various stock rating systems and portfolios. PBF Energy and Delek US surged following Zacks Rank #1 upgrades, while the Zacks #1 Rank portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date. Notable performers included Palantir (up 38.3% over 12 weeks), Adobe (up 27.6%), Thermo Fisher (up 40.2%), and Monolithic Power Systems (up 30.1% since January 5, 2026). The article emphasizes Zacks' track record of outperforming the market since 1988.

  

• Zacks Investment Research 16 sept

  Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

  Quest Diagnostics (DGX) has reached a new 52-week high of $248.65, gaining 42.4% year-to-date with a strong track record of beating earnings estimates. The stock carries a Zacks Rank #2 (Buy) with a B VGM Score, though it trades at a premium valuation of 22.2X current fiscal year EPS versus the industry average of 20.4X. The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries, providing positive tailwinds for the sector.